Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000926617-17-000049
Filing Date
2017-08-11
Accepted
2017-08-11 16:02:19
Documents
34
Period of Report
2017-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q c617-20170630x10q.htm 10-Q 929046
2 EX-31.1 c617-20170630xex31_1.htm EX-31.1 15075
3 EX-31.2 c617-20170630xex31_2.htm EX-31.2 15323
4 EX-32.1 c617-20170630xex32_1.htm EX-32.1 11613
5 GRAPHIC c617-20170630x10qg001.jpg GRAPHIC 18865
  Complete submission text file 0000926617-17-000049.txt   2478383

Data Files

Seq Description Document Type Size
6 EX-101.INS c617-20170630.xml EX-101.INS 317657
7 EX-101.SCH c617-20170630.xsd EX-101.SCH 19459
8 EX-101.CAL c617-20170630_cal.xml EX-101.CAL 28178
9 EX-101.DEF c617-20170630_def.xml EX-101.DEF 58857
10 EX-101.LAB c617-20170630_lab.xml EX-101.LAB 169095
11 EX-101.PRE c617-20170630_pre.xml EX-101.PRE 132915
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
VERMILLION, INC. (Filer) CIK: 0000926617 (see all company filings)

EIN.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34810 | Film No.: 171024995
SIC: 2835 In Vitro & In Vivo Diagnostic Substances